Navigation Links
Forsyth Medical Center's Derrick L. Davis Forsyth Regional Cancer Center to Take Part in Research Trial for Patients with Fast-Growing Brain Tumors
Date:6/25/2009

The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is one of the first sites in the country to participate in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the brain or spinal cord. This third phase of the trial will test the effectiveness of Avastin in conjunction with standard chemotherapy and radiation treatments for patients newly diagnosed with glioblastoma. This phase of the trial will enroll 700 participants nationwide.

Winston-Salem, NC (PRWEB) June 25, 2009 -- The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the brain or spinal cord.

Forsyth Regional Cancer Center (FRCC) is participating in the third phase of the trial, testing the effectiveness of Avastin in conjunction with standard chemotherapy and radiation treatments for patients newly diagnosed with glioblastoma. This phase of the trial will enroll 700 participants nationwide, and FRCC is one of the first sites in the country to participate.

"Avastin has been shown to be effective in treating various types of cancer, with a low risk of serious side effects, so our hope is that it will improve outcomes for patients with brain tumors when it is added to standard-of-care treatments," says Volker Stieber, M.D., a radiation oncologist at the FRCC. "Phase III is the highest level of research for a drug, so we are excited to be part of a study that could advance treatment for patients with this type of cancer."

In May, the U.S. Food and Drug Administration approved the use of Avastin to treat glioblastomas that have not responded to other therapies based on results from two Phase II studies that showed Avastin reduced tumor size in some glioblastoma patients. The new study evaluates this drug in newly diagnosed, never-treated glioblastoma patients.

Glioblastoma is the most common and most aggressive type of primary brain tumor in humans, accounting for about half of all primary brain tumor cases. Despite its prevalence, however, glioblastomas occur in only two to three cases per 100,000 people in North America and Europe. In Forsyth County, three out of four patients diagnosed with glioblastoma are diagnosed at Forsyth Medical Center.

The FRCC is currently screening patients for enrollment in the clinical trial. Eligible patients may qualify if they are newly diagnosed adults able to undergo partial removal of their tumors. Once enrolled, participants will remain in the study for up to one year.

For more information, call the Derrick L. Davis Forsyth Regional Cancer Center at 336-277-8887 or visit http://www.forsythmedicalcenter.org.

About Forsyth Medical Center:
Forsyth Medical Center is part of Novant Health, a not-for-profit integrated group of hospitals and physician clinics, ranked 12th nationally among the 2009 Top 100 Integrated Healthcare Networks, according to an analysis by the SDI health informatics company. Novant staff cares for patients and communities in North and South Carolina. Hospital affiliates include Presbyterian Hospital, Presbyterian Orthopaedic Hospital, Presbyterian Hospital Matthews and Presbyterian Hospital Huntersville in the Charlotte, NC area; Forsyth Medical Center and Medical Park Hospital in Winston-Salem, NC; Thomasville Medical Center in Thomasville, NC; Rowan Regional Medical Center in Salisbury, NC; and Brunswick Community Hospital in Supply, NC. The Novant Medical Group consists of more than 1,060 providers in 361 clinic locations. Other Novant facilities and programs include two nursing homes, outpatient surgery and diagnostic centers, rehabilitation programs and community health outreach programs.

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2568974.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Forsyth launches 1-of-a-kind core service to enable rapid identification of bacterial samples
2. American Dental Association, The Forsyth Institute Collaborate to Pilot Evidence-Based Dentistry Training Course
3. MSU engineering team designs innovative medical device
4. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
5. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
6. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
9. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
10. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
11. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: